For best experience we recommend to activate Javascript in your browser.

17-DMAG

Inh 467214-20-6 Alvespimycin, 17DMAG, 17-(dimethylaminoethylamino)-17-demethoxy-geldanamycin, 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin, 17-desmethoxy-17-n,n-dimethylaminoethylamino-geldanamycin, 17-dimethylaminoethylamino-17-demethoxy-geldanamycin, 17-DMAG, 17-Dimethylaminoethylamino, 17-Demethoxygeldanamycin, [(3R,5S,6R,7S,8E,10S,11S,12Z,14E)-21-[2-(dimethylamino)ethylamino]-6-hydroxy-5,11-dimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate

1 image

Catalog No. ABIN1027735

Quick Overview for 17-DMAG (ABIN1027735)

Application

Inhibition (Inh)

Chemical Name

Alvespimycin, 17DMAG, 17-(dimethylaminoethylamino)-17-demethoxy-geldanamycin, 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin, 17-desmethoxy-17-n,n-dimethylaminoethylamino-geldanamycin, 17-dimethylaminoethylamino-17-demethoxy-geldanamycin, 17-DMAG, 17-Dimethylaminoethylamino, 17-Demethoxygeldanamycin, [(3R,5S,6R,7S,8E,10S,11S,12Z,14E)-21-[2-(dimethylamino)ethylamino]-6-hydroxy-5,11-dimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate

Purpose

Hsp90 inhibitor

Characteristics

Hsp90 inhibitor.

Purity

>98 % (TLC), NMR conforms

Formula

C32H48N4O8

Solubility

Soluble in DMSO (30 mg/ml) and ethanol (10 mg/ml)
Geldanamycin
Inh 30562-34-6 (4E,6Z,8S,9S,10E,12S,13R,14S,16R)-13-hydroxy-8,14,19-trimethoxy-4,10,12,16-tetramethyl-3,20,22-trioxo-2-azabicyclo[16.3.1] docosa-1(21),4,6,10,18-pentaen-9-yl carbamate

Radicicol
Inh 12772-57-5

Geldanamycin- FITC
Inh 30562-34-6 (4E,6Z,8S,9S,10E,12S,13R,14S,16R)-13-hydroxy-8,14,19-trimethoxy-4,10,12,16-tetramethyl-3,20,22-trioxo-2-azabicyclo[16.3.1] docosa-1(21),4,6,10,18-pentaen-9-yl carbamate

5-Azacytidine
Inh Cell-permeable 320-67-2 4-Amino-1-ß-D-ribofuranosyl-1,3,5-triazin-2(1H)-one

Nicotinamide
Inh 98-92-0 Pyridine-3-carboxylic acid amide

SAHA (Vorinostat)
Inh Cell-permeable 149647-78-9 Suberoylanilide-hydroxamic acid

Phenylbutyrate Na
Inh 1716-12-7 4-Phenylbutyric acid, sodium salt

CI-994
Inh 112522-64-2 4-(Acetylamino)-N-(2-aminophenyl)benzamide

Tranylcypromine hemisulfate (±)
Inh Cell-permeable 13492-01-8 Trans (±)-2-phenylcyclopropanamine, hemisulfate salt

Tenovin-1
Inh 380315-80-0 N-[(4-Acetamidophenyl)carbamothioyl]-4-tert-butylbenzamide

Comment

Source: Synthetic.
Appearance: Purple Solid

Restrictions

For Research Use only
Format

Solid

Precaution of Use

Classification: Caution: Substance not yet fully tested. Safety Phrases: S22 - Do not breathe dust S24/25 - Avoid contact with skin and eyes S36/37/39 - Wear suitable protective clothing, gloves and eye/face protection

Handling Advice

Classification: Caution: Substance not yet fully tested. Safety Phrases: S22 - Do not breathe dust S24/25 - Avoid contact with skin and eyes S36/37/39 - Wear suitable protective clothing, gloves and eye/face protection

Storage

-20 °C
Background

17-DMAG is a water soluble & cell-permeable analog of Geldanamycin and 17-AAG. It binds to the APTase site of human Hsp90a with high affinity, has cytotoxic activity against many cancer cell lines, and acts as angiogenesis inhibitor. This Hsp90 inhibitor shows promise in preclinical models. 17-DMAG has excellent bioavailability, is widely distributed to tissues, and is quantitatively metabolized much less than is 17-AAG.

Molecular Weight

616.8

CAS-No

467214-20-6